Haplo-identical Natural Killer (NK) Cells to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM)

NCT04395092 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped The sponsor decided to withdraw this study

Conditions

Acute Myeloid Leukemia (AML)
Myelodysplastic Syndromes (MDS)

Interventions

BIOLOGICAL: K-NK002
PROCEDURE: Conditioning Regimen
PROCEDURE: HaploBMT

Sponsor

Kiadis Pharma

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]